You are here
Hydropothecary ‘gets intimate’ with release of Fleur de Lune, its first medical cannabis oil for personal use
GATINEAU, Quebec, July 16, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“HEXO” or the “Company”) (TSX:HEXO) is proud to announce the launch of Fleur de Lune, an intimate medical cannabis oil.
“With Fleur de Lune, we’re continuing to execute on our innovation and product development strategy. Fleur de Lune is yet another smoke-free medical cannabis option that responds to the evolving needs of our clients and the Canadian marketplace,” adds Sebastien St-Louis, HEXO’s CEO and Co-founder.
Fleur de Lune is a THC oil product based in an odorless, tasteless carrier oil (medium-chain triglyceride or MCT). Each 60ml bottle contains up to 600mg of THC, or 7 to 10mg/ml.
“We’re excited to be launching an intimate oil, which is a completely different use for medical cannabis. We believe Canadians will embrace this discreet way to consume their medicine,” says Sonia Isabel, Vice-President of Sales for HEXO.
Fleur de Lune is HEXO’s latest cannabis oil innovation, which includes Elixir CBD Peppermint and Elixir THC Peppermint. Other smoke-free options include the Decarb line, which won Best New Cannabis Product at the Canadian Cannabis Awards 2017.
Fleur de Lune
$59/60ml spray bottle
HEXO creates and distributes innovative, easy-to-use and easy-to-understand products to serve the Canadian cannabis market. One of the country’s lowest-cost producers, HEXO is rapidly increasing its production capacity in the lead up to the adult-use cannabis market. The Company currently operates with 300,000 sq. ft. of production capacity and has another 1,000,000 sq. ft. expansion set to be complete by year end. HEXO will serve the adult-use market under the HEXO brand, while continuing to serve its medical cannabis clients through the well-known Hydropothecary brand.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.